Design, synthesis and anticancer evaluation of β-carboline-1-one hydantoins

Future Med Chem. 2020 Feb;12(3):183-192. doi: 10.4155/fmc-2019-0276. Epub 2019 Dec 9.

Abstract

Aim: Cancer is a major health burden and a leading cause of death worldwide. We sought to discover potential anticancer molecules with novel scaffold for further development of more active agents to address the issue. Methodology: A series of β-carboline-1-one hydantoins were designed according to a conformational restriction strategy, synthesized via a one-pot Knoevenagel condensation-intramolecular cyclization, and tested in cytotoxicity assays. Results: The study culminated in the identification of 6b and 6c, both of which were found to potently inhibit breast and lung cancer cell lines. Of particular interest was 6c, which was 83 times more potent an inhibitor than 5-fluorouracil in inhibiting MCF-7. Conclusion: This work establishes β-carboline-1-one hydantoin as a promising scaffold in the investigation of anticancer agents.

Keywords: Knoevenagel condensation; anticancer; conformational restriction strategy; intramolecular cyclization; β-carboline-1-one hydantoin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • A549 Cells
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Carbolines / chemical synthesis
  • Carbolines / chemistry
  • Carbolines / pharmacology*
  • Cell Proliferation / drug effects
  • Dose-Response Relationship, Drug
  • Drug Design*
  • Drug Screening Assays, Antitumor
  • Humans
  • Hydantoins / chemical synthesis
  • Hydantoins / chemistry
  • Hydantoins / pharmacology*
  • MCF-7 Cells
  • Molecular Structure
  • Structure-Activity Relationship
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Carbolines
  • Hydantoins